ZA932445B - Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Info

Publication number
ZA932445B
ZA932445B ZA932445A ZA932445A ZA932445B ZA 932445 B ZA932445 B ZA 932445B ZA 932445 A ZA932445 A ZA 932445A ZA 932445 A ZA932445 A ZA 932445A ZA 932445 B ZA932445 B ZA 932445B
Authority
ZA
South Africa
Prior art keywords
man
animals
prevention
treatment
virus infection
Prior art date
Application number
ZA932445A
Inventor
Geraldine Taylor
Edward James Stott
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of ZA932445B publication Critical patent/ZA932445B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA932445A 1992-04-06 1993-04-05 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man ZA932445B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207479A GB9207479D0 (en) 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Publications (1)

Publication Number Publication Date
ZA932445B true ZA932445B (en) 1995-01-05

Family

ID=10713521

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932445A ZA932445B (en) 1992-04-06 1993-04-05 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Country Status (9)

Country Link
EP (1) EP0636182A1 (en)
JP (1) JPH07508401A (en)
KR (1) KR950701386A (en)
AU (1) AU679440B2 (en)
CA (1) CA2133662A1 (en)
GB (1) GB9207479D0 (en)
NZ (1) NZ251405A (en)
WO (1) WO1993020210A1 (en)
ZA (1) ZA932445B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
FR2758331B1 (en) * 1997-01-14 1999-03-05 Univ Bourgogne NEW MEANS FOR DIAGNOSIS, PREVENTION AND TREATMENT FOR CONTAMINATION OR INFECTIONS WITH MUCOUS TROPISM VIRUSES
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
EP1278545A1 (en) * 2000-05-03 2003-01-29 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
AU2001263443A1 (en) * 2000-05-25 2001-12-03 Med Immune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RU2551963C2 (en) 2010-09-09 2015-06-10 Пфайзер Инк. Molecules binding to 4-1bb
FR2970968A1 (en) * 2011-02-01 2012-08-03 Isp Investments Inc NOVEL PEPTIDES INVOLVED IN THE SCF C-KIT SIGNALING PATHWAY AND COMPOSITIONS COMPRISING THE SAME
US9364414B2 (en) 2011-02-01 2016-06-14 Isp Investments Inc. Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (en) * 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート Humanized antibody
CN105073781A (en) 2013-01-11 2015-11-18 加州生物医学研究所 Bovine fusion antibodies
EP3022221B1 (en) * 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
US20210347862A1 (en) * 2018-09-03 2021-11-11 Pontificia Universidad Catolica De Chile Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis
EP4265637A1 (en) * 2020-12-18 2023-10-25 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
CA2087100A1 (en) * 1990-07-19 1992-01-20 Robert M. Chanock Immunotherapeutic method of preventing or treating viral respiratory tract disease
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
ATE231002T1 (en) * 1992-09-16 2003-02-15 Scripps Research Inst HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNZYTIAL VIRUS
WO1994017105A1 (en) * 1993-01-29 1994-08-04 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus

Also Published As

Publication number Publication date
AU3900093A (en) 1993-11-08
GB9207479D0 (en) 1992-05-20
NZ251405A (en) 1997-09-22
JPH07508401A (en) 1995-09-21
EP0636182A1 (en) 1995-02-01
WO1993020210A1 (en) 1993-10-14
CA2133662A1 (en) 1993-10-14
KR950701386A (en) 1995-03-23
AU679440B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
ZA917170B (en) Novel antibodies for treatment and prevention of infection in animals and man
IL132003A0 (en) Antimicrobial prevention and treatment of human immundeficiency virus and other infectious diseases
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0746322A4 (en) Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes
ZA951831B (en) Vaccine for the prevention of respiratory and reproductive diseases of the pig
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
EP0628056A4 (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections.
ZA932308B (en) Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
AU7043694A (en) Method of treatment and prevention of immune complex-induced lung injury
GB9417173D0 (en) Novel treatment of upper respiratory tract infections
HU9402816D0 (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
GB9111885D0 (en) Nerve growth factor for use in the prevention and treatment of viral infections
EP0655919A4 (en) Treatment of human viral infections.
GB2255718B (en) Pharmaceutical composition for treating bacterial and / or viral infection
HU913022D0 (en) Fibroplast increasing factor for treating and preventing virus caused diseases
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
AU4259193A (en) Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
GB9521008D0 (en) Therapeutic treatment of viral infection in humans and animals
EG20171A (en) Treatment of conditions and disease
IL102021A0 (en) Protein-kinase inhibitors for the treatment of human and animal viral diseases
AU3981093A (en) Preparation useful for prevention and treatment of intestinal infections in animals and human beings
ZA948741B (en) Novel treatment of upper respiratory tract infections